Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 115

1.

The effect of capped biparametric magnetic resonance imaging slots on weekly prostate cancer imaging workload.

Sushentsev N, Caglic I, Sala E, Shaida N, Slough RA, Carmo B, Kozlov V, Gnanapragasam VJ, Barrett T.

Br J Radiol. 2020 Feb 3:20190929. doi: 10.1259/bjr.20190929. [Epub ahead of print]

PMID:
31971823
2.

Prostate cancer treatment choices: the GP's role in shared decision making.

Merriel SW, Gnanapragasam V.

Br J Gen Pract. 2019 Nov 28;69(689):588-589. doi: 10.3399/bjgp19X706685. Print 2019 Dec. No abstract available.

PMID:
31780467
3.

Ten-year Mortality, Disease Progression, and Treatment-related Side Effects in Men with Localised Prostate Cancer from the ProtecT Randomised Controlled Trial According to Treatment Received.

Neal DE, Metcalfe C, Donovan JL, Lane JA, Davis M, Young GJ, Dutton SJ, Walsh EI, Martin RM, Peters TJ, Turner EL, Mason M, Bryant R, Bollina P, Catto J, Doherty A, Gillatt D, Gnanapragasam V, Holding P, Hughes O, Kockelbergh R, Kynaston H, Oxley J, Paul A, Paez E, Rosario DJ, Rowe E, Staffurth J, Altman DG, Hamdy FC; ProtecT Study Group.

Eur Urol. 2019 Nov 24. pii: S0302-2838(19)30837-1. doi: 10.1016/j.eururo.2019.10.030. [Epub ahead of print]

4.

Removing rician bias in diffusional kurtosis of the prostate using real-data reconstruction.

Goodburn RJ, Barrett T, Patterson I, Gallagher FA, Lawrence EM, Gnanapragasam VJ, Kastner C, Priest AN.

Magn Reson Med. 2019 Nov 18. doi: 10.1002/mrm.28080. [Epub ahead of print]

PMID:
31737935
5.

Adherence to Active Surveillance Protocols for Low-risk Prostate Cancer: Results of the Movember Foundation's Global Action Plan Prostate Cancer Active Surveillance Initiative.

Kalapara AA, Verbeek JFM, Nieboer D, Fahey M, Gnanapragasam V, Van Hemelrijck M, Lee LS, Bangma CH, Steyerberg EW, Harkin T, Helleman J, Roobol MJ, Frydenberg M; Movember Foundation’s Global Action Plan Prostate Cancer Active Surveillance (GAP3) Consortium.

Eur Urol Oncol. 2020 Feb;3(1):80-91. doi: 10.1016/j.euo.2019.08.014. Epub 2019 Sep 26.

PMID:
31564531
6.

Understanding of prognosis in non-metastatic prostate cancer: a randomised comparative study of clinician estimates measured against the PREDICT prostate prognostic model.

Thurtle DR, Jenkins V, Pharoah PD, Gnanapragasam VJ.

Br J Cancer. 2019 Oct;121(8):715-718. doi: 10.1038/s41416-019-0569-4. Epub 2019 Sep 16.

7.

Informing informed decision-making in primary prostate cancer treatment selection.

Gnanapragasam VJ.

BJU Int. 2020 Feb;125(2):194-196. doi: 10.1111/bju.14910. Epub 2019 Oct 3. No abstract available.

PMID:
31512792
8.

Three-year experience of a dedicated prostate mpMRI pre-biopsy programme and effect on timed cancer diagnostic pathways.

Barrett T, Slough R, Sushentsev N, Shaida N, Koo BC, Caglic I, Kozlov V, Warren AY, Thankappannair V, Pinnock C, Shah N, Saeb-Parsy K, Gnanapragasam VJ, Sala E, Kastner C.

Clin Radiol. 2019 Nov;74(11):894.e1-894.e9. doi: 10.1016/j.crad.2019.06.004. Epub 2019 Jul 6.

PMID:
31288924
9.

Models predicting survival to guide treatment decision-making in newly diagnosed primary non-metastatic prostate cancer: a systematic review.

Thurtle D, Rossi SH, Berry B, Pharoah P, Gnanapragasam VJ.

BMJ Open. 2019 Jun 22;9(6):e029149. doi: 10.1136/bmjopen-2019-029149.

10.

Impact of hospital nephrectomy volume on intermediate- to long-term survival in renal cell carcinoma.

Hsu RCJ, Barclay M, Loughran MA, Lyratzopoulos G, Gnanapragasam VJ, Armitage JN.

BJU Int. 2020 Jan;125(1):56-63. doi: 10.1111/bju.14848. Epub 2019 Jul 15.

11.

Consistent Biopsy Quality and Gleason Grading Within the Global Active Surveillance Global Action Plan 3 Initiative: A Prerequisite for Future Studies.

van der Kwast TH, Helleman J, Nieboer D, Bruinsma SM, Roobol MJ; Movember Foundation's Global Action Plan Prostate Cancer Active Surveillance (GAP3) Consortium, Trock B, Ehdaie B, Carroll P, Filson C, Kim J, Logothetis C, Morgan T, Klotz L, Pickles T, Hyndman E, Moore CM, Gnanapragasam V, Van Hemelrijck M, Dasgupta P, Bangma C, Roobol M, Villers A, Rannikko A, Valdagni R, Perry A, Hugosson J, Rubio-Briones J, Bjartell A, Hefermehl L, Shiong LL, Frydenberg M, Kakehi Y, Chung BH, van der Kwast T, Obbink H, van der Linden W, Hulsen T, de Jonge C, Kattan M, Xinge J, Muir K, Lophatananon A, Fahey M, Steyerberg E, Nieboer D, Zhang L, Guo W, Benfante N, Cowan J, Patil D, Tolosa E, Kim TK, Mamedov A, LaPointe V, Crump T, Kimberly-Duffell J, Santaolalla A, Nieboer D, Olivier JT, Rancati T, Ahlgren H, Mascarós J, Löfgren A, Lehmann K, Lin CH, Hirama H, Lee KS, Jenster G, Auvinen A, Bjartell A, Haider M, van Bochove K, Carter B, Gledhill S, Buzza M, Bangma C, Roobol M, Bruinsma S, Helleman J.

Eur Urol Oncol. 2019 May;2(3):333-336. doi: 10.1016/j.euo.2018.08.017. Epub 2018 Sep 13.

PMID:
31200849
12.

Using prognosis to guide inclusion criteria, define standardised endpoints and stratify follow-up in active surveillance for prostate cancer.

Gnanapragasam VJ, Barrett T, Thankapannair V, Thurtle D, Rubio-Briones J, Domínguez-Escrig J, Bratt O, Statin P, Muir K, Lophatananon A.

BJU Int. 2019 Nov;124(5):758-767. doi: 10.1111/bju.14800. Epub 2019 Jun 2.

PMID:
31063245
13.

Individual prognosis at diagnosis in nonmetastatic prostate cancer: Development and external validation of the PREDICT Prostate multivariable model.

Thurtle DR, Greenberg DC, Lee LS, Huang HH, Pharoah PD, Gnanapragasam VJ.

PLoS Med. 2019 Mar 12;16(3):e1002758. doi: 10.1371/journal.pmed.1002758. eCollection 2019 Mar.

14.

Best practice in active surveillance for men with prostate cancer: a Prostate Cancer UK consensus statement.

Merriel SWD, Hetherington L, Seggie A, Castle JT, Cross W, Roobol MJ, Gnanapragasam V, Moore CM; Prostate Cancer UK Expert Reference Group on Active Surveillance.

BJU Int. 2019 Jul;124(1):47-54. doi: 10.1111/bju.14707. Epub 2019 Mar 7.

15.

The Quest for the Optimal Prostate Biopsy Regime for the 21st Century.

Gnanapragasam VJ, Barrett T.

Eur Urol. 2019 May;75(5):741-742. doi: 10.1016/j.eururo.2018.12.031. Epub 2019 Jan 5. No abstract available.

PMID:
30616948
16.

Repeatability of diffusion-weighted MRI of the prostate using whole lesion ADC values, skew and histogram analysis.

Barrett T, Lawrence EM, Priest AN, Warren AY, Gnanapragasam VJ, Gallagher FA, Sala E.

Eur J Radiol. 2019 Jan;110:22-29. doi: 10.1016/j.ejrad.2018.11.014. Epub 2018 Nov 17.

17.

Using prognosis to guide early detection and treatment selection in non-metastatic prostate cancer.

Gnanapragasam VJ, Barrett T, Massie C, Pacey S, Warren A.

BJU Int. 2019 Apr;123(4):562-563. doi: 10.1111/bju.14637. Epub 2018 Dec 28. No abstract available.

PMID:
30499634
18.

Reasons for Discontinuing Active Surveillance: Assessment of 21 Centres in 12 Countries in the Movember GAP3 Consortium.

Van Hemelrijck M, Ji X, Helleman J, Roobol MJ, van der Linden W, Nieboer D, Bangma CH, Frydenberg M, Rannikko A, Lee LS, Gnanapragasam VJ, Kattan MW; Members of the Movember Foundation's Global Action Plan Prostate Cancer Active Surveillance GAP3 consortium; Members of the Movember Foundation's Global Action Plan Prostate Cancer Active Surveillance GAP3 consortium.

Eur Urol. 2019 Mar;75(3):523-531. doi: 10.1016/j.eururo.2018.10.025. Epub 2018 Oct 29.

PMID:
30385049
19.

Quantification of Total and Intracellular Sodium Concentration in Primary Prostate Cancer and Adjacent Normal Prostate Tissue With Magnetic Resonance Imaging.

Barrett T, Riemer F, McLean MA, Kaggie J, Robb F, Tropp JS, Warren A, Bratt O, Shah N, Gnanapragasam VJ, Gilbert FJ, Graves MJ, Gallagher FA.

Invest Radiol. 2018 Aug;53(8):450-456. doi: 10.1097/RLI.0000000000000470.

PMID:
29969108
20.

Improving the safety and tolerability of local anaesthetic outpatient transperineal prostate biopsies: A pilot study of the CAMbridge PROstate Biopsy (CAMPROBE) method.

Thurtle D, Starling L, Leonard K, Stone T, Gnanapragasam VJ.

J Clin Urol. 2018 May;11(3):192-199. doi: 10.1177/2051415818762683. Epub 2018 Mar 5.

21.

Sequencing of prostate cancers identifies new cancer genes, routes of progression and drug targets.

Wedge DC, Gundem G, Mitchell T, Woodcock DJ, Martincorena I, Ghori M, Zamora J, Butler A, Whitaker H, Kote-Jarai Z, Alexandrov LB, Van Loo P, Massie CE, Dentro S, Warren AY, Verrill C, Berney DM, Dennis N, Merson S, Hawkins S, Howat W, Lu YJ, Lambert A, Kay J, Kremeyer B, Karaszi K, Luxton H, Camacho N, Marsden L, Edwards S, Matthews L, Bo V, Leongamornlert D, McLaren S, Ng A, Yu Y, Zhang H, Dadaev T, Thomas S, Easton DF, Ahmed M, Bancroft E, Fisher C, Livni N, Nicol D, Tavaré S, Gill P, Greenman C, Khoo V, Van As N, Kumar P, Ogden C, Cahill D, Thompson A, Mayer E, Rowe E, Dudderidge T, Gnanapragasam V, Shah NC, Raine K, Jones D, Menzies A, Stebbings L, Teague J, Hazell S, Corbishley C; CAMCAP Study Group, de Bono J, Attard G, Isaacs W, Visakorpi T, Fraser M, Boutros PC, Bristow RG, Workman P, Sander C; TCGA Consortium, Hamdy FC, Futreal A, McDermott U, Al-Lazikani B, Lynch AG, Bova GS, Foster CS, Brewer DS, Neal DE, Cooper CS, Eeles RA.

Nat Genet. 2018 May;50(5):682-692. doi: 10.1038/s41588-018-0086-z. Epub 2018 Apr 16.

22.

Time trends in service provision and survival outcomes for patients with renal cancer treated by nephrectomy in England 2000-2010.

Hsu RCJ, Barclay M, Loughran MA, Lyratzopoulos G, Gnanapragasam VJ, Armitage JN.

BJU Int. 2018 Oct;122(4):599-609. doi: 10.1111/bju.14217. Epub 2018 Apr 20.

23.

The Cambridge Prognostic Groups for improved prediction of disease mortality at diagnosis in primary non-metastatic prostate cancer: a validation study.

Gnanapragasam VJ, Bratt O, Muir K, Lee LS, Huang HH, Stattin P, Lophatananon A.

BMC Med. 2018 Feb 28;16(1):31. doi: 10.1186/s12916-018-1019-5.

24.

A comparison of operative and margin outcomes from surgeon learning curves in robot assisted radical prostatectomy in a changing referral practice.

Jaulim A, Srinivasan A, Hori S, Kumar N, Warren AY, Shah NC, Gnanapragasam VJ.

Ann R Coll Surg Engl. 2018 Mar;100(3):226-229. doi: 10.1308/rcsann.2018.0001. Epub 2018 Feb 27.

25.

Progression and treatment rates using an active surveillance protocol incorporating image-guided baseline biopsies and multiparametric magnetic resonance imaging monitoring for men with favourable-risk prostate cancer.

Thurtle D, Barrett T, Thankappan-Nair V, Koo B, Warren A, Kastner C, Saeb-Parsy K, Kimberley-Duffell J, Gnanapragasam VJ.

BJU Int. 2018 Jul;122(1):59-65. doi: 10.1111/bju.14166. Epub 2018 Mar 8.

26.

"Future-Proofing" Blood Processing for Measurement of Circulating miRNAs in Samples from Biobanks and Prospective Clinical Trials.

Murray MJ, Watson HL, Ward D, Bailey S, Ferraresso M, Nicholson JC, Gnanapragasam VJ, Thomas B, Scarpini CG, Coleman N.

Cancer Epidemiol Biomarkers Prev. 2018 Feb;27(2):208-218. doi: 10.1158/1055-9965.EPI-17-0657. Epub 2017 Dec 18.

27.

Diagnostic evaluation of magnetization transfer and diffusion kurtosis imaging for prostate cancer detection in a re-biopsy population.

Barrett T, McLean M, Priest AN, Lawrence EM, Patterson AJ, Koo BC, Patterson I, Warren AY, Doble A, Gnanapragasam VJ, Kastner C, Gallagher FA.

Eur Radiol. 2018 Aug;28(8):3141-3150. doi: 10.1007/s00330-017-5169-1. Epub 2017 Dec 8.

28.

Corrigendum to "Aiming for a holistic integrated service for men diagnosed with prostate cancer - Definitions of standards and skill sets for nurses and allied healthcare professionals" [Eur. J. Oncol. Nurs. 29 (2017) 31-38].

Lamb AD, Thompson S, Kinsella N, Gerbitz I, Chapman E, Putt L, Bennett S, Thankappannair V, Geoghegan L, Wright N, Stirton-Croft A, Nixon P, Styling A, Whitney D, Hodgson L, Punt L, Longmore J, Carter M, Petch B, Rimmer Y, Russell S, Hughes-Davies L, Mazhar D, Shah NC, Gnanapragasam VJ, Doble A, Bratt O, Kastner C.

Eur J Oncol Nurs. 2017 Oct;30:59. doi: 10.1016/j.ejon.2017.07.008. Epub 2017 Aug 31. No abstract available.

PMID:
29031314
29.

Appraising the relevance of DNA copy number loss and gain in prostate cancer using whole genome DNA sequence data.

Camacho N, Van Loo P, Edwards S, Kay JD, Matthews L, Haase K, Clark J, Dennis N, Thomas S, Kremeyer B, Zamora J, Butler AP, Gundem G, Merson S, Luxton H, Hawkins S, Ghori M, Marsden L, Lambert A, Karaszi K, Pelvender G, Massie CE, Kote-Jarai Z, Raine K, Jones D, Howat WJ, Hazell S, Livni N, Fisher C, Ogden C, Kumar P, Thompson A, Nicol D, Mayer E, Dudderidge T, Yu Y, Zhang H, Shah NC, Gnanapragasam VJ; CRUK-ICGC Prostate Group, Isaacs W, Visakorpi T, Hamdy F, Berney D, Verrill C, Warren AY, Wedge DC, Lynch AG, Foster CS, Lu YJ, Bova GS, Whitaker HC, McDermott U, Neal DE, Eeles R, Cooper CS, Brewer DS.

PLoS Genet. 2017 Sep 25;13(9):e1007001. doi: 10.1371/journal.pgen.1007001. eCollection 2017 Sep.

30.

Influence of hospital volume on nephrectomy mortality and complications: a systematic review and meta-analysis stratified by surgical type.

Hsu RCJ, Salika T, Maw J, Lyratzopoulos G, Gnanapragasam VJ, Armitage JN.

BMJ Open. 2017 Sep 5;7(9):e016833. doi: 10.1136/bmjopen-2017-016833. Review.

31.

Novel three-dimensional bone 'mapping' software can help assess progression of osseous metastases from routine CT.

Thurtle D, Treece GM, Barrett T, Gnanapragasam VJ.

Radiat Oncol. 2017 Aug 30;12(1):143. doi: 10.1186/s13014-017-0880-2.

32.

Comparative Oncologic and Toxicity Outcomes of Salvage Radical Prostatectomy Versus Nonsurgical Therapies for Radiorecurrent Prostate Cancer: A Meta-Regression Analysis.

Philippou Y, Parker RA, Volanis D, Gnanapragasam VJ.

Eur Urol Focus. 2016 Jun;2(2):158-171. doi: 10.1016/j.euf.2015.09.004. Epub 2015 Oct 4. Review.

PMID:
28723532
33.

Aiming for a holistic integrated service for men diagnosed with prostate cancer - Definitions of standards and skill sets for nurses and allied healthcare professionals.

Lamb AD, Thompson S, Kinsella N, Gerbitz I, Chapman E, Putt L, Bennett S, Thankappannair V, Geoghegan L, Wright N, Stirton-Croft A, Nixon P, Styling A, Whitney D, Hodgson L, Punt L, Longmore J, Carter M, Petch B, Rimmer Y, Russell S, Hughes-Davies L, Mazhar D, Shah NC, Gnanapragasam VJ, Doble A, Bratt O, Kastner C.

Eur J Oncol Nurs. 2017 Aug;29:31-38. doi: 10.1016/j.ejon.2017.04.004. Epub 2017 May 11. Erratum in: Eur J Oncol Nurs. 2017 Oct;30:59.

PMID:
28720263
34.

Association Of Plasma And Urinary Mutant DNA With Clinical Outcomes In Muscle Invasive Bladder Cancer.

Patel KM, van der Vos KE, Smith CG, Mouliere F, Tsui D, Morris J, Chandrananda D, Marass F, van den Broek D, Neal DE, Gnanapragasam VJ, Forshew T, van Rhijn BW, Massie CE, Rosenfeld N, van der Heijden MS.

Sci Rep. 2017 Jul 17;7(1):5554. doi: 10.1038/s41598-017-05623-3.

35.

Novel concepts for risk stratification in prostate cancer.

Patel KM, Gnanapragasam VJ.

J Clin Urol. 2016 Dec;9(2 Suppl):18-23. doi: 10.1177/2051415816673502. Epub 2016 Dec 1.

36.

Corrigendum to "Integration of Copy Number and Transcriptomics Provides Risk Stratification in Prostate Cancer: A Discovery and Validation Cohort Study" [EBioMedicine 2 (9) (2015) 1133-1144].

Ross-Adams H, Lamb AD, Dunning MJ, Halim S, Lindberg J, Massie CM, Egevad LA, Russell R, Ramos-Montoya A, Vowler SL, Sharma NL, Kay J, Whitaker H, Clark J, Hurst R, Gnanapragasam VJ, Shah NC, Warren AY, Cooper CS, Lynch AG, Stark R, Mills IG, Grönberg H, Neal DE; CamCaP Study Group.

EBioMedicine. 2017 Mar;17:238. doi: 10.1016/j.ebiom.2017.03.010. Epub 2017 Mar 8. No abstract available.

37.

Expert consensus document: Semantics in active surveillance for men with localized prostate cancer - results of a modified Delphi consensus procedure.

Bruinsma SM, Roobol MJ, Carroll PR, Klotz L, Pickles T, Moore CM, Gnanapragasam VJ, Villers A, Rannikko A, Valdagni R, Frydenberg M, Kakehi Y, Filson CP, Bangma CH; Movember Foundation's Global Action Plan Prostate Cancer Active Surveillance (GAP3) consortium.

Nat Rev Urol. 2017 May;14(5):312-322. doi: 10.1038/nrurol.2017.26. Epub 2017 Mar 14. Review.

38.

The drama of prostate cancer diagnostics.

Bratt O, Hugosson J, Klotz L, Gnanapragasam V.

Lancet Oncol. 2017 Mar;18(3):e132. doi: 10.1016/S1470-2045(17)30121-3. Epub 2017 Mar 2. No abstract available.

PMID:
28271865
39.

Corrigendum to "Comprehensive assessment of estrogen receptor beta antibodies in cancer cell line models and tissue reveals critical limitations in reagent specificity" [Mol. Cell Endocrinol. 440 (2016) 138-150].

Nelson AW, Groen AJ, Miller JL, Warren AY, Holmes KA, Tarulli GA, Tilley WD, Katzenellenbogen BS, Hawse JR, Gnanapragasam VJ, Carroll JS.

Mol Cell Endocrinol. 2017 Mar 5;443:175. doi: 10.1016/j.mce.2017.01.048. No abstract available.

40.

Loss of hSef promotes metastasis through upregulation of EMT in prostate cancer.

Hori S, Wadhwa K, Pisupati V, Zecchini V, Ramos-Montoya A, Warren AY, Neal DE, Gnanapragasam VJ.

Int J Cancer. 2017 Apr 15;140(8):1881-1887. doi: 10.1002/ijc.30604. Epub 2017 Jan 30.

41.

Robotic assisted laparoscopic radical prostatectomy following transrectal compared to transperineal prostate biopsy: surgical, oncological and functional outcomes.

Wadhwa K, Patruno G, Patterson A, Barrett T, Dalia C, Koo BC, Gallagher FA, Serrao E, Warren A, Gnanapragasam V, Shah N, Doble A, Kastner C.

Minerva Urol Nefrol. 2017 Feb;69(1):85-92. doi: 10.23736/S0393-2249.16.02759-4. Epub 2016 Sep 29.

PMID:
28009149
42.

Comprehensive assessment of estrogen receptor beta antibodies in cancer cell line models and tissue reveals critical limitations in reagent specificity.

Nelson AW, Groen AJ, Miller JL, Warren AY, Holmes KA, Tarulli GA, Tilley WD, Katzenellenbogen BS, Hawse JR, Gnanapragasam VJ, Carroll JS.

Mol Cell Endocrinol. 2017 Jan 15;440:138-150. doi: 10.1016/j.mce.2016.11.016. Epub 2016 Nov 23. Erratum in: Mol Cell Endocrinol. 2017 Mar 5;443:175.

43.

Improving clinical prognostic stratification models for men with prostate cancer: a practical step closer to more individualized care without added costs.

Gnanapragasam VJ, Warren AY.

BJU Int. 2017 Mar;119(3):366-367. doi: 10.1111/bju.13721. Epub 2016 Dec 10. Review. No abstract available.

44.

Corrigendum: Fumarate is an epigenetic modifier that elicits epithelial-to-mesenchymal transition.

Sciacovelli M, Gonçalves E, Johnson TI, Zecchini VR, da Costa AS, Gaude E, Drubbel AV, Theobald SJ, Abbo SR, Tran MG, Rajeeve V, Cardaci S, Foster S, Yun H, Cutillas P, Warren A, Gnanapragasam V, Gottlieb E, Franze K, Huntly B, Maher ER, Maxwell PH, Saez-Rodriguez J, Frezza C.

Nature. 2016 Dec 1;540(7631):150. doi: 10.1038/nature20144. Epub 2016 Oct 19. No abstract available.

PMID:
27760119
45.

Incorporating multiparametric MRI staging and the new histological Grade Group system improves risk-stratified detection of bone metastasis in prostate cancer.

Thurtle D, Hsu RC, Chetan M, Lophatananon A, Hubbard R, Gnanapragasam VJ, Barrett T.

Br J Cancer. 2016 Nov 22;115(11):1285-1288. doi: 10.1038/bjc.2016.353. Epub 2016 Nov 1.

46.

Comparison of initial and tertiary centre second opinion reads of multiparametric magnetic resonance imaging of the prostate prior to repeat biopsy.

Hansen NL, Koo BC, Gallagher FA, Warren AY, Doble A, Gnanapragasam V, Bratt O, Kastner C, Barrett T.

Eur Radiol. 2017 Jun;27(6):2259-2266. doi: 10.1007/s00330-016-4635-5. Epub 2016 Oct 24.

47.

Evolution and oncological outcomes of a contemporary radical prostatectomy practice in a UK regional tertiary referral centre.

Gnanapragasam VJ, Thurtle D, Srinivasan A, Volanis D, George A, Lophatananon A, Stearn S, Warren AY, Lamb AD, Shaw G, Sharma N, Thomas BC, Tran MG, Neal DE, Shah NC.

BJU Int. 2016 Nov;118(5):779-784. doi: 10.1111/bju.13513. Epub 2016 May 24.

48.

The Prostate Health Index adds predictive value to multi-parametric MRI in detecting significant prostate cancers in a repeat biopsy population.

Gnanapragasam VJ, Burling K, George A, Stearn S, Warren A, Barrett T, Koo B, Gallagher FA, Doble A, Kastner C, Parker RA.

Sci Rep. 2016 Oct 17;6:35364. doi: 10.1038/srep35364.

49.

Mortality Among Men with Advanced Prostate Cancer Excluded from the ProtecT Trial.

Johnston TJ, Shaw GL, Lamb AD, Parashar D, Greenberg D, Xiong T, Edwards AL, Gnanapragasam V, Holding P, Herbert P, Davis M, Mizielinsk E, Lane JA, Oxley J, Robinson M, Mason M, Staffurth J, Bollina P, Catto J, Doble A, Doherty A, Gillatt D, Kockelbergh R, Kynaston H, Prescott S, Paul A, Powell P, Rosario D, Rowe E, Donovan JL, Hamdy FC, Neal DE; ProtecT study group.

Eur Urol. 2017 Mar;71(3):381-388. doi: 10.1016/j.eururo.2016.09.040. Epub 2016 Oct 6.

50.

Fumarate is an epigenetic modifier that elicits epithelial-to-mesenchymal transition.

Sciacovelli M, Gonçalves E, Johnson TI, Zecchini VR, da Costa AS, Gaude E, Drubbel AV, Theobald SJ, Abbo SR, Tran MG, Rajeeve V, Cardaci S, Foster S, Yun H, Cutillas P, Warren A, Gnanapragasam V, Gottlieb E, Franze K, Huntly B, Maher ER, Maxwell PH, Saez-Rodriguez J, Frezza C.

Nature. 2016 Aug 31;537(7621):544-547. doi: 10.1038/nature19353. Erratum in: Nature. 2016 Dec 1;540(7631):150.

Supplemental Content

Loading ...
Support Center